REG - Hemogenyx Pharma Plc - Issue of convertible loan notes

Hemogenyx PharmaceuticalsAnnouncement

01/09/2025 15:15

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250901:nRSA5125Xa&default-theme=true

RNS Number : 5125X  Hemogenyx Pharmaceuticals PLC  01 September 2025

1 September 2025

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION AS STIPULATED UNDER THE UK
VERSION OF THE MARKET ABUSE REGULATION NO 596/2014 WHICH IS PART OF ENGLISH
LAW BY VIRTUE OF THE EUROPEAN (WITHDRAWAL) ACT 2018, AS AMENDED.  ON
PUBLICATION OF THIS ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS
INFORMATION IS CONSIDERED TO BE IN THE PUBLIC DOMAIN.

HEMOGENYX PHARMACEUTICALS PLC

("Hemogenyx Pharmaceuticals" or the "Company")

Issue of convertible loan notes to raise £620,000

Hemogenyx Pharmaceuticals plc (LSE: HEMO) is pleased to announce that it has
raised £620,000 through the issue of convertible loan notes (the "CLNs"). As
the Company continues the clinical trial of HG-CT-1, its CAR-T cell therapy
for relapsed or refractory acute myeloid leukemia, it was approached by a
small investor group offering to provide funding to support the ongoing
clinical trial.

Convertible Loan Notes

To support the clinical trial, the Company has raised £620,000 (gross and
net) through the issuance of CLNs at a fixed conversion price of £5.30 per
share, being the closing share price on 29 August 2025.

The CLNs, which are non-interest bearing, will automatically convert following
an increase in the Company's headroom restrictions under the FCA's Prospectus
Rules, allowing for the issuance of conversion shares without requiring an
approved prospectus. This conversion is expected to take place on or after 15
November 2025.

Vladislav Sandler, CEO of Hemogenyx Pharmaceuticals, commented:

"We are very encouraged by the progress of our Phase I clinical trial of
HG-CT-1, and we are grateful for the continued support of our investors. Their
participation in this funding reflects confidence in our strategy and
long-term vision. These CLNs strengthen our balance sheet, extend our
financial runway, and enable us to maintain momentum in the clinical
development of HG-CT-1 for patients with relapsed or refractory acute myeloid
leukemia."

Application for Admission

The Company will apply for the admission of the 116,982 Ordinary Shares,
issued to subscribers upon the conversion of the CLNs, to trading on the
London Stock Exchange. Admission is expected to become effective after 15
November 2025.

Upon admission, the new Ordinary Shares will rank pari passu in all respects
with the existing Ordinary Shares and will be entitled to receive all future
dividends and distributions declared, paid, or made on the Company's ordinary
share capital.

UK Market Abuse Regulation (UK MAR) Disclosure

Certain information contained in this announcement would have been inside
information for the purposes of Article 7 of Regulation No 596/2014 (as it
forms part of UK domestic law by virtue of the European Union (Withdrawal) Act
2018) until the release of this announcement. The person responsible for
arranging for the release of this announcement on behalf of Hemogenyx
Pharmaceuticals plc is Dr Vladislav Sandler, Chief Executive Officer &
Co-Founder.

 

Enquiries:

 Hemogenyx Pharmaceuticals plc                                   https://hemogenyx.com (https://hemogenyx.com/)
 Dr Vladislav Sandler, Chief Executive Officer & Co-Founder      headquarters@hemogenyx.com (mailto:headquarters@hemogenyx.com)
 Peter Redmond, Director                                         peter.redmond@hemogenyx.com (mailto:peter.redmond@hemogenyx.com)
 SP Angel Corporate Finance LLP                                  Tel: +44 (0)20 3470 0470
 Matthew Johnson, Vadim Alexandre, Adam Cowl
 Peterhouse Capital Limited                                      Tel: +44 (0)20 7469 0930
 Lucy Williams, Duncan Vasey, Charles Goodfellow

About Hemogenyx Pharmaceuticals plc

Hemogenyx Pharmaceuticals is a publicly traded company (LSE: HEMO)
headquartered in London, with its US operating subsidiaries, Hemogenyx
Pharmaceuticals LLC and Immugenyx LLC, located in New York City .

The Company is a clinical stage biopharmaceutical group developing new
medicines and treatments to treat blood and autoimmune diseases. Hemogenyx
Pharmaceuticals is developing several distinct and complementary product
candidates, as well as platform technologies that it uses as engines for novel
product development.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  IODUARSRVSUKRAR